Evaluation of <i>RAS</i> Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients
In this study we evaluated both~ K- and N-<i>RAS</i> mutations in plasma samples from patients with metastatic colorectal cancer by means of the BEAMing technology, and we assessed their diagnostic performance compared to <i>RAS</i> analyses performed on tissue. The sensitivi...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-05-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/12/11/1458 |
| _version_ | 1827739693318406144 |
|---|---|
| author | Elena Lastraioli Alessandra Bettiol Jessica Iorio Elvira Limatola Daniele Checcacci Erica Parisi Cristina Bianchi Annarosa Arcangeli Mauro Iannopollo Francesco Di Costanzo Marco Di Lieto |
| author_facet | Elena Lastraioli Alessandra Bettiol Jessica Iorio Elvira Limatola Daniele Checcacci Erica Parisi Cristina Bianchi Annarosa Arcangeli Mauro Iannopollo Francesco Di Costanzo Marco Di Lieto |
| author_sort | Elena Lastraioli |
| collection | DOAJ |
| description | In this study we evaluated both~ K- and N-<i>RAS</i> mutations in plasma samples from patients with metastatic colorectal cancer by means of the BEAMing technology, and we assessed their diagnostic performance compared to <i>RAS</i> analyses performed on tissue. The sensitivity of BEAMing in identifying <i>KRAS</i> mutations was of 89.5%, with a fair specificity. The agreement with tissue analysis was moderate. The sensitivity for <i>NRAS</i> was high with a good specificity, and the agreement between tissue analysis and BEAMing was fair. Interestingly, significantly higher mutant allele fraction (MAF) levels were detected in patients with G2 tumors, liver metastases, and in those who did not receive surgery. <i>NRAS</i> MAF level was significantly higher in patients with mucinous adenocarcinoma and for those with lung metastases. A sharp increase in the MAF values was observed in patients who moved towards disease progression. More strikingly, molecular progression always anticipated the radiological one in these patients. These observations pave the way to the possibility of using liquid biopsy to monitor patients during treatment, and to enable oncologists to anticipate interventions compared to radiological analyses. This will allow time to be saved and ensure a better management of metastatic patients in the near future. |
| first_indexed | 2024-03-11T03:10:49Z |
| format | Article |
| id | doaj.art-ae1ad3dff9b4426e8f30f8181f5e4ce9 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-11T03:10:49Z |
| publishDate | 2023-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-ae1ad3dff9b4426e8f30f8181f5e4ce92023-11-18T07:40:22ZengMDPI AGCells2073-44092023-05-011211145810.3390/cells12111458Evaluation of <i>RAS</i> Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer PatientsElena Lastraioli0Alessandra Bettiol1Jessica Iorio2Elvira Limatola3Daniele Checcacci4Erica Parisi5Cristina Bianchi6Annarosa Arcangeli7Mauro Iannopollo8Francesco Di Costanzo9Marco Di Lieto10Department of Experimental and Clinical Medicine, University of Florence, 50134 Florence, ItalyDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, ItalyDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, ItalyMedical Oncology, S. Jacopo Hospital, 51100 Pistoia, ItalyMedical Oncology, S. Jacopo Hospital, 51100 Pistoia, ItalyMedical Oncology, S. Jacopo Hospital, 51100 Pistoia, ItalyMedical Oncology, S. Jacopo Hospital, 51100 Pistoia, ItalyDepartment of Experimental and Clinical Medicine, University of Florence, 50134 Florence, ItalyMedical Oncology, S. Jacopo Hospital, 51100 Pistoia, ItalyMedical Oncology Unit, Azienda Ospedaliero-Universitaria Careggi, Largo Brambilla 3, 50134 Florence, ItalyMedical Oncology, S. Jacopo Hospital, 51100 Pistoia, ItalyIn this study we evaluated both~ K- and N-<i>RAS</i> mutations in plasma samples from patients with metastatic colorectal cancer by means of the BEAMing technology, and we assessed their diagnostic performance compared to <i>RAS</i> analyses performed on tissue. The sensitivity of BEAMing in identifying <i>KRAS</i> mutations was of 89.5%, with a fair specificity. The agreement with tissue analysis was moderate. The sensitivity for <i>NRAS</i> was high with a good specificity, and the agreement between tissue analysis and BEAMing was fair. Interestingly, significantly higher mutant allele fraction (MAF) levels were detected in patients with G2 tumors, liver metastases, and in those who did not receive surgery. <i>NRAS</i> MAF level was significantly higher in patients with mucinous adenocarcinoma and for those with lung metastases. A sharp increase in the MAF values was observed in patients who moved towards disease progression. More strikingly, molecular progression always anticipated the radiological one in these patients. These observations pave the way to the possibility of using liquid biopsy to monitor patients during treatment, and to enable oncologists to anticipate interventions compared to radiological analyses. This will allow time to be saved and ensure a better management of metastatic patients in the near future.https://www.mdpi.com/2073-4409/12/11/1458<i>KRAS</i><i>NRAS</i>liquid biopsymetastatic colorectal cancer |
| spellingShingle | Elena Lastraioli Alessandra Bettiol Jessica Iorio Elvira Limatola Daniele Checcacci Erica Parisi Cristina Bianchi Annarosa Arcangeli Mauro Iannopollo Francesco Di Costanzo Marco Di Lieto Evaluation of <i>RAS</i> Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients Cells <i>KRAS</i> <i>NRAS</i> liquid biopsy metastatic colorectal cancer |
| title | Evaluation of <i>RAS</i> Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients |
| title_full | Evaluation of <i>RAS</i> Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients |
| title_fullStr | Evaluation of <i>RAS</i> Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients |
| title_full_unstemmed | Evaluation of <i>RAS</i> Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients |
| title_short | Evaluation of <i>RAS</i> Mutational Status in Liquid Biopsy to Monitor Disease Progression in Metastatic Colorectal Cancer Patients |
| title_sort | evaluation of i ras i mutational status in liquid biopsy to monitor disease progression in metastatic colorectal cancer patients |
| topic | <i>KRAS</i> <i>NRAS</i> liquid biopsy metastatic colorectal cancer |
| url | https://www.mdpi.com/2073-4409/12/11/1458 |
| work_keys_str_mv | AT elenalastraioli evaluationofirasimutationalstatusinliquidbiopsytomonitordiseaseprogressioninmetastaticcolorectalcancerpatients AT alessandrabettiol evaluationofirasimutationalstatusinliquidbiopsytomonitordiseaseprogressioninmetastaticcolorectalcancerpatients AT jessicaiorio evaluationofirasimutationalstatusinliquidbiopsytomonitordiseaseprogressioninmetastaticcolorectalcancerpatients AT elviralimatola evaluationofirasimutationalstatusinliquidbiopsytomonitordiseaseprogressioninmetastaticcolorectalcancerpatients AT danielecheccacci evaluationofirasimutationalstatusinliquidbiopsytomonitordiseaseprogressioninmetastaticcolorectalcancerpatients AT ericaparisi evaluationofirasimutationalstatusinliquidbiopsytomonitordiseaseprogressioninmetastaticcolorectalcancerpatients AT cristinabianchi evaluationofirasimutationalstatusinliquidbiopsytomonitordiseaseprogressioninmetastaticcolorectalcancerpatients AT annarosaarcangeli evaluationofirasimutationalstatusinliquidbiopsytomonitordiseaseprogressioninmetastaticcolorectalcancerpatients AT mauroiannopollo evaluationofirasimutationalstatusinliquidbiopsytomonitordiseaseprogressioninmetastaticcolorectalcancerpatients AT francescodicostanzo evaluationofirasimutationalstatusinliquidbiopsytomonitordiseaseprogressioninmetastaticcolorectalcancerpatients AT marcodilieto evaluationofirasimutationalstatusinliquidbiopsytomonitordiseaseprogressioninmetastaticcolorectalcancerpatients |